Wyndly
Financials
Estimates*
USD | 2021 | 2022 | 2023 |
---|---|---|---|
Revenues | <1m | <1m | <1m |
% growth | - | 133 % | 29 % |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | - | |
N/A | Early VC | ||
* | $2.0m | Seed | |
Total Funding | $2.0m |
Recent News about Wyndly
EditWyndly is a health-tech startup that offers a unique solution to individuals suffering from allergies. The company operates in the healthcare sector, specifically focusing on allergy treatment. Wyndly's primary service is providing customized, clinically proven, at-home treatment plans that aim to retrain the immune system to stop responding to allergy triggers. This is achieved by exposing the immune system to small doses of the allergens over time.
The company's target clients are individuals who suffer from common indoor and outdoor environmental allergies. Wyndly's services begin with an easy at-home allergy test, which detects the 40 most common allergens, including pet dander, pollen, and dust. Once the test is completed, it is returned to Wyndly's CLIA-certified lab for analysis.
Wyndly's business model is centered on providing a convenient and effective solution for allergy sufferers. The company generates revenue by selling its at-home allergy tests and subsequent personalized treatment plans. The treatment plans are designed to gradually reduce the client's allergic reactions, with the expectation that they will no longer need to rely on standard allergy medication.
In summary, Wyndly is a health-tech startup that offers a unique, convenient, and effective solution for individuals suffering from allergies. The company operates in the healthcare sector, providing at-home allergy tests and personalized treatment plans designed to retrain the immune system to stop responding to allergy triggers.
Keywords: Health-tech, Allergy Treatment, At-home Testing, Personalized Treatment Plans, Immune System Retraining, Environmental Allergies, CLIA-certified Lab, Allergy Medication, Healthcare Sector, Startup.